SERA PROGNOSTICS, INC. (SERA) research
SERA PROGNOSTICS, INC.- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $2.09
- As of
SERA PROGNOSTICS, INC. (SERA): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-19.
As of . Source: SEC EDGAR filings for SERA. Method and limitations.
Share the SERA intelligence card
See the full SERA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SERA on one page. Preview it with sample data, then open it live with a free account.
Preview the SERA dossierActive signals for SERA
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 13.9%, EPS $-0.18 vs $-0.1581 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 21.6% - EPS $-0.16 vs $-0.204 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 30.3% - EPS $-0.16 vs $-0.2295 estimate
- mediumEARNINGS_BEAT
Beat consensus by 21.6% - EPS $-0.16 vs $-0.204 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 17.4% - EPS $-0.16 vs $-0.1938 estimate
FREE, NO ACCOUNT
Every signal on SERA, as it fires
New filings, 13F moves and cross asset signals on SERA land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SERA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 81749D107 · 2026Q2 | $135K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 81749D107 · 2026Q2 | $75K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 81749D107 · 2026Q2 | $30K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SERA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
SERA against its peers
SERA's operating margin of -45066.7% ranks in the 2nd percentile of 23 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-02-28.
| Metric | SERA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 81000 USD | 33.6M USD | 2 | 23 |
| Gross margin | n/a | 52.7% | n/a | 19 |
| Operating margin | -45066.7% | -55.8% | 2 | 23 |
| Net margin | -39417.3% | -66.4% | 2 | 23 |
| Return on equity | -42.3% | -86.8% | 73 | 19 |
Peers (23): ZOMDF, LUNG, LNSR, CVRX, HYPR, ECOR, MYO, POSC, APYX, MDNC, OM, TELA, RPID, COCH, LUCD, MDAI, XTNT, NNOX, SRTS, OWLT, SNWV, QTRX, EBRCZ. Left out: RTGN (no annual filing), TLTFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-02-28. Every figure is one full fiscal year read from one annual filing (SERA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SERA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SERAand get the insider, 13F, options, and confluence read in one view.